ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
72 announcements with these filters
Gujarat Themis Biosyn Limited incorporated a wholly owned subsidiary, Themis Biosyn Japan Limited, in Japan. This strategic expansion marks the company's direct entry into the Japanese market.
Gujarat Themis Biosyn incorporated a wholly owned subsidiary in Japan named Themis Biosyn Japan Limited. This expansion strengthens the company's international pharmaceutical business footprint.
Gujarat Themis Biosyn scheduled a May 25, 2026 board meeting. Directors will consider FY26 audited financial results and recommend a potential equity dividend.
Gujarat Themis Biosyn Limited has issued a Postal Ballot notice to seek shareholder approval via special resolutions. The resolutions include increasing the company's borrowing limits, creating charges on assets, and enhancing limits for loans, guarantees, and investments. Voting concludes on June 4, 2026.
Gujarat Themis Biosyn Limited has issued a Postal Ballot notice to seek shareholder approval via special resolutions. The resolutions propose increasing the company's borrowing limits and limits for loans, guarantees, and investments under Sections 180 and 186 of the Companies Act, 2013. The voting period ends on June 4, 2026.
Gujarat Themis Biosyn Limited has issued a Postal Ballot notice to approve increasing its borrowing and investment limits to ₹3,500 Crore each. These limits will support strategic initiatives, including a proposed acquisition of anti-tuberculosis brands from Sanofi. Remote e-voting commences on 6th May 2026 and concludes on 4th June 2026.
Gujarat Themis Biosyn Limited is acquiring 13 established branded generic products from Sanofi for €158 million (₹1,722.2 Crore). The acquisition covers 55 countries across Europe, Middle East, and Africa. This strategic move strengthens GTBL’s global anti-infective platform and provides access to regulated markets without acquiring manufacturing facilities or employees.
Gujarat Themis Biosyn Limited is acquiring 13 branded generic products from Sanofi for Euro 158 million (approx. ₹1,722.2 Crore). The asset-light acquisition targets markets in Europe, Middle East, and Africa. The deal strengthens GTBL's global anti-infective platform and is expected to conclude by December 2026.
Gujarat Themis Biosyn is acquiring Sanofi’s global anti-TB and anti-infective portfolio (13 brands) for ~€158M to expand into 55+ countries.
Gujarat Themis Biosyn Ltd signed an agreement to acquire Sanofi's global Anti-TB and Anti-Infective portfolio for EURO 158 million (₹1,722.20 Crore). The deal includes 13 brands across 55+ countries, enabling global forward integration into finished dosage formulations. The transaction is expected to close by Q3FY27, significantly enhancing the company's international footprint and margin profile.
Gujarat Themis Biosyn Limited has agreed to acquire 13 anti-tuberculosis and anti-infective brands from Sanofi for ₹1,722.2 Crore (Euro 158 million). The acquisition provides immediate access to regulated markets in Europe, Middle East, and Africa. The transaction is expected to close by December 2026, strengthening GTBL's global generic pharmaceuticals platform.
Gujarat Themis Biosyn Ltd announced the results of its postal ballot conducted via e-voting. Shareholders approved the re-appointment of Mrs. Kirandeep Madan as an Independent Director and authorized material related party transactions with Themis Medicare Limited. Both resolutions were passed with the requisite majority.